Two real-world studies completed by PHAR in partnership with Otsuka Pharmaceuticals Development & Commercialization, Inc. and H. Lundbeck A/S were recently published in Advances in Therapy and the Journal of Medical Economics. Together the studies highlight potential treatment options that may reduce healthcare costs in patients with chronic mental illness. The Advances in Therapy article focused on the association between timing of augmentation of antidepressants (ADs) with antipsychotics (APs) and healthcare costs in patients with major depressive disorder. Adding an AP earlier in patients who had inadequately responded to first-line ADs reduces overall healthcare costs. The Journal of Medical Economics article examined medication adherence to oral atypical APs and the impact on psychiatric-related hospitalizations and associated costs in patients with bipolar I disorder (BD-I). Better medication adherence to oral atypical APs was associated with fewer psychiatric-related hospitalizations and lower costs in patients with BD-I. The full text of both articles, as well as related posters, can be accessed on the PHAR website.
Archives for 2018
Research focusing on schizophrenia, major depressive disorder, and bipolar I disorder conducted by PHAR and supported by Otsuka Pharmaceuticals Development & Commercialization, Inc. and H. Lundbeck A/S was well-represented at ISPOR Asia Pacific 2018. One study focusing on the effect of timing of long-acting injectable initiation in patients with schizophrenia was selected as an oral presentation, and four others were presented as posters. A study on the impact of comorbid substance abuse on costs in bipolar I disorder won the Best Poster General Research Presentation. The posters and related manuscripts can be accessed on the PHAR website.
A study done by PHAR in partnership with Prothena Biosciences Inc., was recently published in the Journal of Comparative Effectiveness Research. The study estimated the healthcare utilization and costs in amyloid light-chain (AL) amyloidosis. The authors identified AL amyloidosis patients in claims data from 2007 to 2015 and reported inpatient hospitalizations, emergency department visits, non-ED outpatient service visits, and pharmacy utilization. The study found that the general prescribing practices changed over time, with the use of bortezomib increasing and the use of melphalan decreasing. Healthcare utilization and costs decreased between the first and second year after diagnosis. The full text of the study can be read here.
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Symposium, two of PHAR’s newest studies were presented. One study done in partnership with Akcea Therapeutics estimated helathcare utilization and cost among patients with hereditary transtheyretin amyloidosis (hATTR) by analyzing insurance claims. Another study, in partnership with Otsuka Pharmaceutical, examined the effectiveness of long-acting injectables in reducing psychiatric hospitalization among patients with bipolar I disorder.
Three studies conducted by the secondary data analysis team at PHAR were presented at the AMCP Managed Care & Specialty Pharmacy Annual Meeting held in Boston, MA. The studies focused on different disease areas and outcomes, with one study on the health care utilization and costs of newly diagnosed AL amyloidosis, another study on adherence to atypical antipsychotics among patients with bipolar disorder, and another on the disease burden of hereditary transthyretin amyloidosis. All studies were well-received at AMCP 2018, and the posters can be viewed on the PHAR website here.